Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

    Please enter search terms.

    RO7837195

    Other names: RG6730; RO7837195

    Modality: p40 x TL1A bispecific antibody

    Disease State: Ulcerative colitis (UC)

    Summary

    RO7837195 is an investigational p40 x TL1A bispecific antibody that is proposed to simultaneously inhibit two key targets that play a central role in inflammatory bowel disease (IBD) pathology, interleukin (IL)-12/IL-23 and tumor necrosis factor-like ligand 1A (TL1A), with a single molecule.1-4

    Clinical Trials

    RO7837195
    NCT ID Study Phase Enrollment Status Study Title
    NCT06979336 Phase II Recruiting A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) View details

    Proposed Mechanism of Action

    IL-12/IL-23 and TL1A are cytokines that play a central role in promoting and amplifying inflammation in IBD.1-3 IL-12 and IL-23 share the p40 subunit, promote intestinal inflammation, and are strongly associated with IBD pathology.1 TL1A acts as a key amplifier of multiple immune signaling pathways implicated in the key features of IBD, including chronic inflammation, excessive tissue remodeling, and intestinal barrier damage.2,3 IL-12/IL-23 and TL1A are clinically validated targets for the treatment of  IBD.5-8

    RO7837195 is an investigational p40 x TL1A bispecific antibody that is proposed to simultaneously inhibit two key targets that play a central role in IBD pathology, IL-12/IL-23 and TL1A, with a single molecule.1-4

    1. Verstockt B, Salas A, Sands BE, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):433-446. doi:10.1038/​s41575-023-00768-1
    2. Xu WD, Li R, Huang AF. Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review. Front Immunol. 2022;13:891328. doi:10.3389/​fimmu.2022.891328
    3. Bamias G, Martin C 3rd, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171(9):4868-4874. doi:10.4049/​jimmunol.171.9.4868
    4. Roche Pipeline: RG6730. Accessed on Dec 10, 2025 from https://www.roche.com/​solutions/​pipeline
    5. Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025;120(6):1187-1224. doi:10.14309/​ajg.0000000000003463
    6. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2024;167(7):1307-1343. doi: 10.1053/​j.gastro.2024.10.001
    7. Danese S, Klopocka M, Scherl EJ, et al. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol. 2021;19(11):2324-2332.e6. doi:10.1016/​j.cgh.2021.06.011
    8. Danese S, Allegretti JR, Schreiber S, et al. Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2025:10(10):882-895. doi:10.1016/​S2468-1253(25)00129-3

    Looking for more information?

    Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

    Connect with an MSL
    Submit a Request

    Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT

    TOP

    • DC
      dendritic cell

    • DR3
      death receptor 3

    • IBD
      inflammatory bowel disease

    • IL
      interleukin

    • ILC
      innate lymphoid cell

    • Mφ
      macrophage

    • PK
      pharmacokinetics

    • TH
      helper T

    • TL1A
      tumor necrosis factor-like ligand 1A

    • UC
      ulcerative colitis

    +